Structure Therapeutics appointed Matthew Lang, J.D. as chief operating officer and general counsel, bringing in an executive with more than 15 years of experience across biopharmaceutical companies.
Lang most recently served as chief legal officer and secretary at Metsera, where he helped guide the company through its proposed acquisition by Pfizer valued at up to $10 billion. Before that, he was chief business and legal officer at Lyell Immunopharma and held several executive roles at Myovant Sciences, where he helped lead phase 3 development, global approval and commercialization of Myfembree and Orgovyx.
The company said Lang’s appointment comes as it prepares to move aleniglipron into phase 3. Raymond Stevens, Structure Therapeutics’ chief executive, said the company is entering that stage with “one of the most promising late-stage assets” in the obesity market.
Lang also previously served as managing director and general manager of Myovant’s European operations in Basel, Switzerland, overseeing ex-U.S. business operations. Earlier in his career, he held roles of increasing seniority at Gilead Sciences and worked as an attorney at Dechert.
He earned a bachelor’s degree in classical studies from Queen’s University at Kingston and a J.D. from the University of Pennsylvania Law School. The market has reacted to these announcements by moving the company's shares -4.01% to a price of $46.20. Check out the company's full 8-K submission here.
